What is B. Riley’s Forecast for CGTX FY2025 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – B. Riley issued their FY2025 earnings per share estimates for Cognition Therapeutics in a note issued to investors on Tuesday, November 26th. B. Riley analyst M. Mamtani expects that the company will earn ($0.83) per share for the year. B. Riley currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.93) per share.

A number of other equities research analysts also recently issued reports on CGTX. Chardan Capital reissued a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Cognition Therapeutics in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.00.

Cognition Therapeutics Price Performance

Shares of NASDAQ:CGTX opened at $0.40 on Wednesday. The company has a market capitalization of $16.53 million, a P/E ratio of -0.41 and a beta of 1.34. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The business’s 50 day simple moving average is $0.47 and its 200 day simple moving average is $1.11.

Institutional Investors Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. CM Management LLC lifted its stake in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after purchasing an additional 25,000 shares during the last quarter. Sigma Planning Corp lifted its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the last quarter. Virtu Financial LLC bought a new stake in Cognition Therapeutics during the third quarter worth $27,000. Finally, Bangor Savings Bank lifted its stake in Cognition Therapeutics by 41.6% during the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after purchasing an additional 10,000 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.